About us
Scintomics Molecular, Applied Theranostics Technologies (ATT) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy
The well-known GRP Module Series became part of ATT in April when ATT took over the Module business from its Parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.
ATT Worldwide
Our Distributor Network
ATT Worldwide
Customer Worldwide
Our Scintomics/att History
2006
Founded by Prof. H. J. Wester (TUM)
Hotbox series & Gallelut (still running at several customer sites)
2010
Start of:
Innovative tracer techniques and Radiopharmaceuticals for Imaging and Therapy, (IP protected in several countries)
2018
Scintomics Molecular, att GmbH founded by Scintomics GmbH
New portfolio with cassettes, consumables and precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy.
2020
att takes over Module Business from Scintomics
new siGRP-Module:
for production of the two SiFA-based radiopharmaceuticals [F-18]siPSMA and [F-18]SiFAlin-TATE – ready to compete with Ga-68 !
Our Gallery
